NADAC acquisition cost data for MEPROBAMATE 400 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 62332002031 | $5.07 | 2022-04-20 | Rx |
| 69097097507 | $5.07 | 2022-04-20 | Rx |
| 62332002031 | $5.07 | 2022-04-20 | Rx |
| 69097097507 | $5.07 | 2022-04-20 | Rx |
| 62332002031 | $5.07 | 2022-04-20 | Rx |
| 69097097507 | $5.07 | 2022-04-20 | Rx |
| 62332002031 | $5.07 | 2022-04-20 | Rx |
| 69097097507 | $5.07 | 2022-04-20 | Rx |
| 62332002031 | $5.07 | 2022-04-20 | Rx |
| 69097097507 | $5.07 | 2022-04-20 | Rx |
Generic: Meprobamate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $2.0M | 5,122 | 1,255 | $4.39 |
| 2020 | $2.3M | 5,489 | 1,068 | $4.73 |
| 2021 | $2.0M | 4,795 | 918 | $4.85 |
| 2022 | $1.7M | 4,335 | 811 | $4.66 |
| 2023 | $1.5M | 3,689 | 719 | $4.85 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $234.7K | 547 | 85 |
| Florida | $197.6K | 587 | 129 |
| California | $116.4K | 346 | 68 |
| Pennsylvania | $89.8K | 241 | 41 |
| Michigan | $73.0K | 171 | 29 |
| Texas | $62.6K | 136 | 26 |
| North Carolina | $59.0K | 107 | 21 |
| Missouri | $58.7K | 101 | 18 |
| Indiana | $45.4K | 99 | 23 |
| Connecticut | $44.7K | 87 | 15 |
| New Jersey | $44.0K | 101 | 25 |
| Washington | $39.5K | 77 | 15 |
| Louisiana | $34.6K | 63 | N/A |
| Tennessee | $32.6K | 69 | 13 |
| Virginia | $32.5K | 77 | 16 |
| Illinois | $29.5K | 47 | 18 |
| Ohio | $29.0K | 78 | 27 |
| Georgia | $28.5K | 79 | 13 |
| Arkansas | $26.1K | 42 | N/A |
| Massachusetts | $22.4K | 67 | 14 |
| Minnesota | $21.7K | 48 | 11 |
| Arizona | $20.6K | 39 | N/A |
| Maryland | $20.0K | 57 | 13 |
| Oregon | $16.7K | 35 | N/A |
| West Virginia | $14.3K | 60 | N/A |
| Delaware | $13.1K | 21 | N/A |
| Nebraska | $11.2K | 17 | N/A |
| New Hampshire | $9.8K | 28 | N/A |
| South Carolina | $9.3K | 21 | N/A |
| Wisconsin | $9.2K | 28 | N/A |
| Kentucky | $8.5K | 35 | N/A |
| Iowa | $7.2K | 14 | N/A |
| Maine | $6.0K | 18 | N/A |
| District of Columbia | $6.0K | 14 | N/A |
| Kansas | $5.6K | 36 | N/A |
| Oklahoma | $5.5K | 17 | N/A |
| Idaho | $4.4K | 15 | N/A |
| Rhode Island | $3.6K | 13 | N/A |
| Alaska | $3.2K | 12 | N/A |
| Nevada | $3.1K | 16 | N/A |
| Alabama | $3.0K | 15 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.